NEW YORK (GenomeWeb) – Genomics England has contracted with WuXi Nextcode, a wholly owned subsidiary of WuXi AppTec, to provide clinical interpretations of genomics data from patients with cancer and rare disease as part of the UK’s 100,000 Genomes Project.
NHS clinicians will use the company’s database and its analysis and reporting infrastructure to identify causative variants in both rare disease and cancer cases. “We are delighted to be working with WuXi Nextcode,” Augusto Rendon, director of bioinformatics at Genomics England, said in a statement. “Their sequence analysis platform will help us to return high-quality variant interpretation results back to clinicians and make a direct impact on patient care.”
Hannes Smarason, president and COO of WuXi Nextcode, added “we look forward to putting our technology to work for NHS patients through interpretation and by applying the knowledge gained to advance the development of targeted new therapies for cancer and a range of rare conditions.”
In September, Genomics England announced that it had signed contracts with Congenica and Omicia to interpret genomic data from the first 8,000 patients participating in the UK’s 100K project. It also said at the time that it would keep working with Nanthealth and WuXiNextcode and also with reserve bidder Lockheed Martin, who is partnering with Cypher Genomics for the project.